Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension

INTRODUCTION: Long-term safety and efficacy of upadacitinib in patients with active ankylosing spondylitis (AS) has not been previously reported. METHODS: In SELECT-AXIS 1, patients receiving placebo were switched to upadacitinib 15 mg once daily at week 14 while patients initially randomised to upa...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Heijde, Désirée, Deodhar, Atul, Maksymowych, Walter P, Sieper, Joachim, Van den Bosch, Filip, Kim, Tae-Hwan, Kishimoto, Mitsumasa, Östör, Andrew J, Combe, Bernard, Sui, Yunxia, Duan, Yuanyuan, Wung, Peter K, Song, In-Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Spondyloarthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335045/
https://www.ncbi.nlm.nih.gov/pubmed/35896281
http://dx.doi.org/10.1136/rmdopen-2022-002280

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335045/
https://www.ncbi.nlm.nih.gov/pubmed/35896281
http://dx.doi.org/10.1136/rmdopen-2022-002280

Ejemplares similares